

## 7 Literaturverzeichnis

- (1) Avigan, D.: Dendritic cells: development, function and potential use for cancer immunotherapy. *Blood Rev* **13**: 51-64, 1999
- (2) Baluna, R., Rizo, R., Gordon, B. E., Ghetie, V., Vitetta, E. S.: Evidence for a structural motif in toxins and interleukin-2 that may be responsible for binding to endothelial cells and initiating vascular leak syndrome. *Proc Nat Acad Sci* **96**: 3957-3962, 1999
- (3) Baselga, J., Tripathy, D., Mendelsohn, J., Baughman, S., Benz, C. C., Dantis, L., Sklarin, N. T., Seidman, A. D., Hudis, A., Moore, J. and et al.: Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer. *Semin Oncol* **26**: 78-83, 1999
- (4) Birnboim, H. C., Doly, J.: A rapid alkaline lysis procedure for screening recombinant plasmid DNA. *Nucleic Acids Res* **7**: 1513-1522, 1979
- (5) Boon, T., Cerottini, J.-C., Van den Eynde, B., van der Bruggen, P., Van Pel, A.: Tumor antigens recognized by T lymphocytes. *Annu Rev Immunol* **12**: 337-365, 1994
- (6) Boulnois, G. J.: *Gene Cloning and Analysis. A Laboratory Guide*. Blackwell Scientific Publications, S. 66, 1987
- (7) Boyer, C. M., Pusztai, L., Wiener, J. R., Xu, F. J., Dean, G. S., Bast, B. S., O'Briant, C. K., Greenwald, M., DeSombre, K. A., Bast, R. C. Jr.: Relative cytotoxic activity of immunotoxins reactive with different epitopes on the extracellular domain of the c-ErbB-2 (HER-2/neu) gene product p185. *Int J Cancer* **12**: 525-531, 1999
- (8) Brichard, V., Van Pel, A., Wölfel, T., Wölfel, C., De Plaen, E., Lethe, B., Coulie, P., Boon, T.: The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. *J Exp Med* **178**: 489-495, 1993
- (9) Brugger, W., Brossart, P., Scheduling, S., Stuhler, G., Heinrich, K., Reichardt, V., Grunebach, F., Buhning, H. J., Kanz, L.: Approaches to dendritic cell-based immunotherapy after peripheral blood stem cell transplantation. *Ann N Y Acad Sci* **872**: 363-371, 1999
- (10) Burney, T. L., Rockove, S., Eiseman, J. L., Kyprianou, N: Partial growth suppression of human prostate cancer cells by the Krev-1 suppressor gene. *Prostate* **25**: 177-188, 1994
- (11) Caamano, J., DiRado, M., Iizasa, T., Momiki, S., Fernandes, E., Ashendel, C., Noda, M., Klein-Szanto, A. J.: Partial suppression of tumorigenicity in a human lung cancer cell line transfected with Krev-1. *Mol Carcinog* **6**: 252-259, 1992
- (12) Cai, X. & Garen, A.: Comparison of fusion phage libraries displaying V<sub>H</sub> or single-chain Fv antibody fragments derived from the antibody repertoire of a vaccinated melanoma patient as a source of melanoma-specific targeting molecules. *Proc Nat Acad Sci* **94**: 9261-9266, 1996
- (13) Celis, E., Tsai, V., Crimi, C., DeMars, R., Wentworth, P. A., Chesnut, R. W., Grey, H. M., Sette, A., Serra, H. M.: Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes. *Proc Natl Acad Sci* **91**: 2105-2109, 1994
- (14) CESAME Manual Version 2.0, Department of Pathology, University Hospital Maastricht, 1996
- (15) Chan, A. D. & Morton, D. L.: Active immunotherapy with allogeneic tumor cell vaccines: present status. *Semin Oncol* **25**: 611-622, 1998
- (16) Chen, Y.-T., Scanlan, M. J., Sahin, U., Türeci, Ö., Gure, A. O., Tsang, S., Williamson, B., Stockert, E., Pfreundschuh, M, Old, L. J.: A testicular antigen

- aberrantly expressed in human cancers detected by autologous antibody screening. *Proc Natl Acad Sci* **94**: 1914-1918, 1997
- (17) Chomczynski, P. & Sacchi, N: Single step method of RNA isolation by acid guanidium thiocyanate-pheno-chloroform extraction. *Anal Biochem* **162**: 156-159, 1987
- (18) Chowdhury, P. S., Viner, J. L., Beers, R., Pastan, I.: Isolation of a high-affinity stable single-chain Fv specific for mesothelin from a DNA-immunized mice by phage display and construction of a recombinant immunotoxin with anti-tumor activity. *Proc Natl Acad Sci* **95**: 669-674, 1998
- (19) Clair, T., Miller, W. R., Cho-Chung, Y. S.: Prognostic significance of the expression of a ras protein with a molecular weight of 21,000 by human breast cancer. *Cancer Res* **47**: 5290-5293, 1987
- (20) Clark, J. G. & Der, C. J.: Aberrant function of the ras signal transduction pathway in human breast cancer. *Breast Cancer Res Treat* **35**: 133-144, 1995
- (21) Clark, J. G., Kinch, M. S., Rogers-Graham, K., Sebti, S. M., Hamilton, A. D., Der, C. J.: The ras-related protein rheb is farnesylated and antagonizes ras signaling and transformation. *J Biol Chem* **16**: 10608-10615, 1997
- (22) Clark, J. I. & Weiner, L. M.: Biologic treatment of human cancer. *Curr Probl Cancer* **19**: 185-262, 1995
- (23) Coiffier, B., Haioun, C., Ketterer, N., Engert, A., Tilly, H., Ma, D., Johnson, P., Lister, A., Feuring-Buske, M., Radford, J.A. and et al.: Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. *Blood* **92**: 1927-1932, 1998
- (24) Collier, R. J.: Diphtheria toxin: Mode of action and structure. *Bacteriol Rev* **39**: 54-85, 1975
- (25) Cote, R. J., Morrissey, D. M., Houghton, A. N., Thomson, T. M., Daly, M. E., Oettgen, H. F., Old, L. J.: Specificity analysis of human monoclonal antibodies reactive with cell surface and intracellular antigens. *Proc Natl Acad Sci* **83**: 2959-2963, 1986
- (26) Croce, M. V., Price, M. R., Segal-Eiras, A.: Expression of monoclonal-antibody-defined antigens in fractions isolated from human breast carcinomas and patients' serum. *Cancer Immunol Immunother* **40**: 132-137, 1995
- (27) Curnow, R. T.: Clinical experience with CD64-directed immunotherapy. An overview. *Cancer Immunol Immunother* **45**: 210-215, 1997
- (28) Czerniak, B., Chen, R., Tuziak, T., Markiewski, M., Kram, A., Gorczyca, W., Deitch, D., Herz, F., Koss, L. G.: Expression of ras oncogene p21 in relation to regional spread of human breast carcinomas. *Cancer* **63**: 2008-2013, 1989
- (29) Davis, T. A., Czerwinski, D. K., Levy, R.: Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression. *Clin Cancer Res* **5**: 611-615, 1999
- (30) De Gast, G. C., van de Winkel, J. G. J., Bast, B. E. J. E. G.: Clinical perspectives of bispecific antibodies in cancer. *Cancer Immunol Immunother* **45**: 121-123, 1997
- (31) DeNardo, S. J., Kramer, E. L., O'Donnell, R. T., Richman, C. M., Salako, Q. A., Shen, S., Noz, M., Glenn, S. D., Ceriani, R. L., DeNardo, G. L.: Radioimmunotherapy for breast cancer using indium-111/yttrium-90 BrE-3: results of a phase I clinical trial. *J Nucl Med* **38**: 1180-1185, 1997
- (32) Desai, A. S., Wang, X., Noronha, E. J., Kageshita, T., Ferrone, S.: Characterization of human Anti-High Molecular Weight-Melanoma Associated Antigen single-chain Fv fragments isolated from a phage display antibody library. *Cancer Res* **58**: 2417-2425, 1998

- (33) Dropcho, E. J., Chen, Y.-T., Posner, J. B., Old, L. J.: Cloning of a brain protein identified by autoantibodies from a patient with paraneoplastic cerebellar degeneration. *Proc Natl Acad Sci* **84**: 4552-4556, 1987
- (34) Endo, Y., Mitsui, K., Motizuki, M., Tsurugi, K.: The mechanism of action of ricin and related lectins on eukaryotic ribosomes. The site and characteristics of the modification in 28 S ribosomal RNA caused by the toxins. *J Biol Chem* **262**: 5908-5912, 1987
- (35) Epstein, N. & Epstein, M.: The hybridoma technology: I. Production of monoclonal antibodies. *Advances Biotechnol Proc* **6**: 179-218, 1986
- (36) Fiorentini, S., Matczak, E., Gallo, R. C., Reitz, M. S., Keydar, I., Watkins, B. A.: Humanization of an antibody recognizing a breast cancer specific epitope by CDR-grafting. *Immunotechnology* **3**: 45-59, 1997
- (37) Gallin, W. J., Prediger, E. A., Edelman, G. M., Cunningham, B. A.: Isolation of a cDNA clone for the liver cell adhesion molecule (L-CAM). *Proc Natl Acad Sci* **82**: 2809-2813, 1985
- (38) Gieffers, C., Koriath, F., Heimann, P., Ungermann, C., Frey, J.: Mitofilin is a transmembrane protein of the inner mitochondrial membrane expressed as two isoforms. *Exp Cell Res* **232**: 395-399, 1997
- (39) Griffiths, A. D. & Duncan, A. R.: Strategies for selection of antibodies by phage display. *Curr Opin Biotechnol* **9**: 102-108, 1998
- (40) Grossbard, M. L., Fidas, P., Kinsella, J., O'Toole, J., Lambert, J. M., Blattler, W. A., Esseltine, D., Braman, G., Nadler, L. M., Anderson, K. C.: Anti-B4-blocked ricin: a phase II trial of 7 day continuous infusion in patients with multiple myeloma. *Br J Haematol* **102**: 509-515, 1998
- (41) Hartmann, F., Renner, C., Pfreundschuh, M.: Anti-CD16/CD30 bispecific antibodies as possible treatment for refractory Hodgkin's disease. *Leuk Lymphoma* **31**: 385-392, 1998
- (42) Hay, B. & Short, J. M. *Strategies* **5**: 16-18, 1992
- (43) Henderikx, P., Kandilogiannaki, M., Petrarca, C., von Mensdorff-Pouilly, S., Hilgers, J. H., Krambovitis, E., Arends, J.-W., Hoogenboom, H. R.: Human single-chain Fv antibodies to MUC1 core peptide selected from phage display libraries recognize unique epitopes and predominantly bind adenocarcinoma. *Cancer Res* **58**: 4324-4332, 1998
- (44) Herlyn, D. & Birebent, B.: Advances in cancer vaccine development. *Ann Med* **31**: 66-78, 1999
- (45) Hoogenboom, H. R., de Bruine, A. P., Hufton, S. E., Hoet, R. M., Arends, J.-W., Roovers, R. C.: Antibody phage display technology and its applications. *Immunotechnology* **4**: 1-20, 1998
- (46) Hoogenboom, H. R., Griffiths, A. D., Johnson, K. S., Chiswell, D. J., Hudson, P., Winter, G.: Multi-subunit proteins on the surface of filamentous phage: methodologies for displaying antibody (Fab) heavy and light chains. *Nucleic Acids Research* **19**: 4133-4137, 1991
- (47) Hoogenboom, H. R., Lutgerink, J. T., Pelsers, M. M., Rousch, M. J., Coote, J., van Neer, N., de Bruine, A., van Nieuwenhoven, F. A., Glatz, J. F., Arends, J.-W.: Selection dominant and nonaccessible epitopes on cell-surface receptors revealed by cell-panning with a large phage antibody library. *Eur J Biochem* **260**: 774-784, 1999
- (48) Horton, R. M., Hunt, H. D., Ho, S. N., Pullen, J. K., Pease, L. R.: Engineering hybrid genes without the use of restriction enzymes: gene splicing by overlap extension. *Gene* **77**: 61-68, 1989

- (49) Hsu, F. J., Benike, C., Fagnoni, F., Liles, T. M., Czerwinski, D., Taidi, B., Engleman, E. G., Levy, R.: Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. *Nat Med* **1**: 52-58, 1996
- (50) Hufton, S. E., Moerkerk, P. T., Meulemans, E. V., de Bruine, A., Arends, J.-W., Hoogenboom, H. R.: Phage display of cDNA repertoires: the pVI display system and its applications for the selection of immunogenic ligands. *J Immunol Methods* **231**: 39-51, 1999
- (51) Huston, J. S., Levinson, D., Mudgett-Hunter, M., Tai, M. S., Novotny, J., Margolies, M. N., Ridge, R. J., Brucoleri, R. E., Haber, E., Crea, R. and et al.: Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in *Escherichia coli*. *Proc Natl Acad Sci* **85**: 5879-5883, 1988
- (52) Huston, J. S., McCartney, J., Tai, M. S., Mottola-Hartshorn, C., Jin, D., Warren, F., Keck, P., Oppermann, H.: Medical applications of single chain antibodies. *Int Rev Immunol* **10**: 195-217, 1993
- (53) Iglewski, B. H., Liu, P. V., Kabat, D.: Pseudomonas aeruginosa exotoxin A diphosphate-ribosylation of mammalian elongation factor 2 in vitro and in vivo. *Infect Immun* **15**: 138-144, 1977
- (54) Jerpseth, B., Greener, A., Short, J. M., Viola, J., Kretz, P. L. *Strategies* **5**: 81-83, 1992
- (55) Kaminski, M. S., Zasadny, K. R., Francis, I. R., Fenner, M. C., Ross, C. W., Milik, A. W., Estes, J., Tuck, M., Regan, D., Fisher, S. and et al.: Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. *J Clin Oncol* **14**: 1974-1981, 1996
- (56) Kay, B. K., Winter, J., McCafferty, J.: Phage display of peptides and proteins. A laboratory manual. Academic Press, 1996
- (57) Klimka, A., Barth, S., Matthey, B., Roovers, R., Lemke, H., Hansen, H., Arends, J.-W., Diehl, V., Hoogenboom, H. R., Engert, A.: An anti-CD30 single-chain Fv selected by phage display and fused to Pseudomonas exotoxin A (Ki-4(scFv)-ETA') is a potent immunotoxin against a Hodgkin-derived cell line. *Br J Cancer* **80**: 1214-1222, 1999
- (58) Köhler, G. & Milstein, C.: Continuous cultures of fused cells secreting antibody of predefined specificity. *Nature* **256**: 495-497, 1975
- (59) Kupsch, J.-M., Tidman, N. H., Kang, N. V., Truman, H., Hamilton, S., Patel, N., Newton Bishop, J. A., Leigh, I. M., Crowe, J. S.: Isolation of human tumor-specific antibodies by selection of an antibody phage library on melanoma cells. *Clin Cancer Res* **5**: 925-931, 1999
- (60) Landau, N. R., St. John, T. P., Weissman, I. L., Wolf, S. C., Silverstone, A. E., Baltimore, D.: Cloning of terminal transferase cDNA by antibody screening. *Proc Natl Acad Sci* **81**: 5836-5840, 1984
- (61) Lasfargues, E. Y., Coutinho, W. G., Redfield, E. S.: Isolation of two human tumor epithelial cell lines from solid breast carcinomas. *J Natl Cancer Inst* **61**: 967-978, 1978
- (62) Leach, S. D., Berger, D. H., Davidson, B. S., Curley, S. A., Tainsky, M. A.: Enhanced Krev-1 expression inhibits the growth of pancreatic adenocarcinoma cells. *Pancreas* **16**: 491-498, 1998
- (63) Lundy, J., Grimson, R., Mishriki, Y., Chao, S., Oravez, S., Fromowitz, F., Viola, M. V.: Elevated ras oncogene expression correlates with lymph node metastases in breast cancer patients. *J Clin Oncol* **4**: 1321-1325, 1986
- (64) Luykx-de Bakker, S. A., de Gruijl, T. D., Scheper, R. J., Wagstaff J., Pinedo, H. M.: Dendritic cells: A novel therapeutic modality. *Ann Oncol* **10**: 21-27, 1999

- (65) Mao, S., Gao, C., Lo, C. H., Wirsching, P., Wong, C. H., Janda, K. D.: Phage-display selection of high-affinity human single-chain antibodies to tumor-associated carbohydrate antigens sialyl Lewisx and Lewisx. *Proc Natl Acad Sci* **96**: 6953-6958, 1999
- (66) Marks, J. D., Hoogenboom, H. R., Bonnert, T. P., McCafferty, J., Griffiths, A. D., Winter, G.: By-passing immunization. Human antibodies from V-gene libraries displayed on phage. *J Mol Biol* **222**: 581-597, 1991
- (67) Martius, G., Breckwoldt, M., Pfeleiderer, A.: *Lehrbuch der Gynäkologie und Geburtshilfe*: 534-558, 1994
- (68) Mc Laughlin, P., White, C. A., Grillo-Lopez, A. J., Maloney, D. G.: Clinical status and optimal use of rituximab for B-cell lymphomas. *Oncology* **12**: 1763-1769, 1998
- (69) McCafferty, J., Fitzgerald, K. J., Earnshaw, J., Chiswell, D., J., Link, J., Smith, R., Kenten, J.: Selection and rapid purification of murine antibody fragments that bind a transition state analog by phage display. *Appl Biochem Biotechnol* **47**: 157-171, discussion 171-173, 1994
- (70) Meredith, R. F., Khazaeli, M. B., Grizzle, W. E., Orr, R. A., Plott, G., Urist, M. M., Liu, T., Russel, C. D., Wheeler, R. H., Schlom, J., and et al.: Direct localization comparison of murine and chimeric B72.3 antibodies in patients with colon cancer. *Hum Antibodies Hybridomas* **4**: 190-197, 1993
- (71) Minafra, S., Morello, V., Glorioso, F., La Fiura, A. M., Tomasino, R. M., Feo, S., McIntosh, D., Woolley, D. E.: A new cell line (8701-BC) from primary ductal infiltrating carcinoma of human breast. *Br J Cancer* **60**: 185-192, 1989
- (72) Miyakis, S., Sourvinos, G., Spandidos, D. A.: Differential expression and mutation of the ras family genes in human breast cancer. *Biochem Biophys Res Commun* **251**: 609-612, 1998
- (73) Mizuki, N., Kimura, M., Ohno, S., Miyata, S., Sato, M., Ando, H., Ishihara, M., Goto, K., Watanabe, S., Yamazaki, M.: Isolation of cDNA and genomic clones of a human-ras-related GTP-binding protein gene and its chromosomal localization to the long arm of chromosome 7, 7q36. *Genomics* **34**: 114-118, 1996
- (74) Moon, A., Kim, M. S., Kim, T. G., Kim, S. H., Kim, H. E., Chen, Y., Q., Kim, H. R.: H-ras, but not N-ras, induces an invasive phenotype in human breast epithelial cells: a role for MMP-2 in the H-ras-induced invasive phenotype. *Int J Cancer* **85**: 176-181, 2000
- (75) Morse, M. A., Deng, Y., Coleman, D., Hull, S., Kitrell-Fisher, E., Nair, S., Schlom, J., Ryback, M. E., Lyster, H. K.: A phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen. *Clin Cancer Res* **5**: 1331-1338, 1999
- (76) Multani, P. S., O'Day, S., Nadler, L. M., Grossbard, M. L.: Phase II clinical trial of bolus infusion anti-B4 blocked ricin immunoconjugate in patients with relapsed B-cell non-Hodgkin's lymphoma. *Clin Cancer Res* **4**: 2599-2604, 1998
- (77) Munro, S. & Pelham, H. R.: An Hsp70-like protein in the ER: identity with the 78 kd glucose-regulated protein and immunoglobulin heavy chain binding protein. *Cell* **46**: 291-300
- (78) Mutuberría, R., Hoogenboom, H. R., van der Linden, E., de Bruine, A. P., Roovers, R. C.: Model systems to study the parameters determining the success of phage antibody selections on complex antigens. *J Immunol Methods* **231**: 65-81, 1999
- (79) Nawrath, M., Pavlovic, J., Dummer, R., Schultz, J., Strack, B., Heinrich, J., Moelling, K.: Reduced melanoma tumor formation in mice immunized with DNA

- expressing the melanoma specific antigen gp100/pmell17. *Leukemia* **13**: pS48-51, 1999
- (80) Nestle, F. O., Alijagic, S., Gilliet, M., Sun, Y., Grabbe, S., Dummer, R., Burg, G., Schadendorf, D.: Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. *Nat Med* **4**: 328-332, 1998
- (81) Nishimura, R., Nagao, K., Miyayama, H., Matsuda, M., Baba, K., Matsuoka, Y., Ueno, Y., Ymashita, H., Nomura, K., Ichguchi, O. and et al.: Expression of ras oncogene p21 in relation to prognostic factors of human breast cancer. *Gan To Kagaku Ryoho* **18**: 2271-2274, 1991
- (82) Odgren, P. R., Toukatly, G., Bangs, P. L., Gilmore, R., Fey, E. G.: Molecular characterization of mitofilin (HMP), a mitochondria-associated protein with predicted coiled coil and intermembrane space targeting domains. *J Cell Sci* **109**: 2253-2264, 1996
- (83) Old, L. J.: Cancer immunology: the search for specificity-G:H:A: Clowes memorial lecture. *Cancer Res* **41**: 361-375, 1981
- (84) Onrust, S. V., Lamb, H. M., Balfour, J. A.: Rituximab. *Drugs* **58**: 79-88, 1999
- (85) Pegram, M. D. & Slamon, D. J.: Combination therapy with trastuzumab (Herceptin) and cisplatin for chemoresistant metastatic breast cancer: evidence for receptor-enhanced chemosensitivity. *Semin Oncol* **26**: 89-95, 1999
- (86) Pirofski, L. Casadevall, A., Rodriguez, L., Zuckier, L., Scharff, M. D.: Current state of hybridoma technology. *J Clin Immunol* **10**: 5S-12S, 1990
- (87) Rabe, T., Gynäkologie und Geburtshilfe, edition medizin VCH: 260-272, 1990
- (88) Rain, J. D. & Billotey, C.: Radioimmunotherapy of lymphomas and leukemias. *Pathol Biol* **46**: 341-345, 1998
- (89) Reisfeld, R. A., Yang, H. M., Muller, B. and et al.: Promises, problems and prospects of monoclonal antibody-drug conjugates for cancer therapy. *Antib Immunconj Radiopharm* **2**: 217-224, 1989
- (90) Reiter, Y. & Pastan, I.: Recombinant Fv immunotoxins and Fv fragments as novel agents for cancer therapy and diagnosis. *Trends Biotechnol* **16**: 513-520, 1998
- (91) Ridgway, J. B. B., Ng, E., Kern, J. A., Lee, J., Brush, J., Goddard, A., Carter, P.: Identification of a human anti-CD55 single-chain Fv by subtractive panning of a phage library using tumor and nontumor cell lines. *Cancer Res* **59**: 2718-2723, 1999
- (92) Rochlitz, C. F., Scott, G. K., Dodson, J. M., Liu, E., Dollbaum, C., Smith, H. S., Benz, C. C.: Incidence of activating ras oncogene mutations associated with primary and metastatic breast cancer. *Cancer Res* **49**: 357-360, 1989
- (93) Rodriguez, R. L. & Denhardt, D. T.: *Vectors. A survey of molecular cloning vectors and their uses*. Butterworths Publishers, 1988
- (94) Sahin, U., Türeci, Ö., Schmitt, H., Cochlovius, B., Johannes, T., Schmits, R., Stenner, F., Luo, G., Schobert, I., Pfreundschuh, M.: Human neoplasms elicit specific immune responses in the autologous host. *Immunonolgy* **92**: 11810-11813, 1995
- (95) Sambrook, J., Fritsch, E. F., Maniatis, T.: *Molecular Cloning-A Laboratory Manual*. Cold Spring Harbor Laboratory Press: 8.75, 1989
- (96) Sanger, F., Coulson, A. R., Hong, G. F., Hill, D. F., Petersen, G. B.: Nucleotide sequence of bacteriophage lambda DNA. *J Mol Biol* **162**: 729-773, 1982
- (97) Sanger, F., Nicklen, S., Coulson, A. R.: DNA sequencing with chain terminating inhibitors. *Proc Natl Acad Sci* **74**: 5463-5467, 1977
- (98) Scanlan, M. J., Chen, Y.-T., Williamson, B., Gure, A. O., Stockert, E., Gordan, J. D., Türeci, Ö., Sahin, U., Pfreundschuh, M., Old, L. J.: Characterization of human

- cancer colon antigens recognized by autologous antibodies. *Int J Cancer* **76**: 652-658, 1998
- (99) Schier, R., Marks, J. D., Wolf, E. J., Apell, G., Wong, C., McCartney, J. E., Bookman, M. A., Huston, J. S., Houston, L. L., Weiner, L. M.: In vitro and in vivo characterization of a human anti-c-erbB-2 single-chain Fv isolated from a filamentous phage antibody library. *Immunotechnology* **1**: 73-81, 1995
- (100) Schmidt-Matthiesen, H.: *Gynäkologie und Geburtshilfe*: 504, 1992
- (101) Schnell, R., Vitetta, E., Schindler, J., Barth, S., Winkler, U., Borchmann, P., Hansmann, M. I., Diehl, V., Ghetie, V., Engert, A.: Clinical trials with an anti-CD25 ricin A-chain experimental and immunotoxin (RFT5-SMPT-dgA) in Hodgkin's lymphoma. *Leuk Lymphoma* **30**: 525-537, 1998
- (102) Schwarzbauer, J. E., Tamkun, J. W., Lemischka, I. R., Hynes, R. O.: Three different fibronectin mRNAs arise by alternative splicing within the coding region. *Cell* **35**: 421-431, 1983
- (103) Scott, A. M. & Welt, S.: Antibody-based immunological therapies. *Curr Opin Immunol* **9**: 717-722, 1997
- (104) Segal-Eiras, A. & Croce, M. V.: Breast cancer associated mucin: a review. *Allergol Immunopathol (Madr)* **25**: 176-181, 1997
- (105) Short, J. M., Fernandez, J. M., Sorge, J. A., Huse, W. D.: Lambda ZAP: a bacteriophage lambda expression vector with in vivo excision properties. *Nucleic Acids Res* **16**: 7583-75600, 1988
- (106) Smith, C. A., Pollice, A. A., Gu, L- P., Brown, K. A., Singh, S. G., Janocko, L. E., Johnson, R., Julian, T., Hyams, D., Wolmark, N.: Correlations among p53, Her-2/neu, and ras overexpression and aneuploidy by multiparameter flow cytometry in human breast cancer: evidence for a common phenotypic evolutionary pattern in infiltrating ductal carcinoma. *Clin Cancer Res* **6**: 112-126, 2000
- (107) Smith, G. P.: Filamentous fusion phage: Novel expression vectors that display cloned antigens on the surface of the virion. *Science* **228**: 1315-1317, 1985
- (108) Takahashi, T., Yamaguchi, T., Kitamura, K., Noguchi, A., Honda, M.: Monoclonal antibody-drug conjugate therapy for patients with colorectal cancer. *Tohoku J Exp Med* **168**: 371-374, 1992
- (109) Tanaka, M., Ozaki, S., Osakada, F., Mori, K., Okubo, M., Nakao, K.: Cloning of a follistatin-related protein as a novel autoantigen in systemic rheumatic diseases. *Int Immunol* **10**: 1305-1314, 1998
- (110) Tedder, T. F. & Engel, P.: CD20: a regulator of cell-cycle progression and B lymphocytes. *Immunol Today* **15**: 450-454, 1994
- (111) Traversari, C., van der Bruggen, P., van den Eynde, B., Hainaut, P., Lemoine, C., Ohta, N., Old, L., Boon, T.: Transfection and expression of a gene coding for a human melanoma antigen recognized by autologous cytolytic T lymphocytes. *Immunogenetics* **35**: 145-152, 1992
- (112) Türeci, Ö., Sahin, U., Pfreundschuh, M.: Serological analysis of human tumor antigens: molecular definition and implications. *Mol Med Today*: 342-349, 1997
- (113) Türeci, Ö., Schmitt, H., Fadle, N., Pfreundschuh, M., Sahin, U.: Molecular definition of a novel human galectin which is immunogenic in patients with Hodgkin's disease. *J Biol Chem* **272**: 6416-6422, 1997
- (114) Tuting, T., Gambotto, A., de Leo, A., Lotze, M. T., Robbins, P. D., Storkus, W. J.: Induction of tumor antigen-specific immunity using plasmid DNA immunization in mice. *Cancer Gene Ther* **6**: 73-80, 1999
- (115) Vaughan, T. J., Osbourn, J. K., Tempest, P. R.: Human antibodies by design. *Nature Biotech* **16**: 535-539, 1998

- (116) Vaughan, T. J., Williams, A. J., Pritchard, K., Osbourn, J. K., Pope, A. R., Earnshaw, J. C., McCafferty, J., Hodits, R. A., Wilton, J., Johnson, K. S.: Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library. *Nat Biotechnol* **14**: 309-314, 1996
- (117) Vetterlein, D.: Monoclonal antibodies: Production, purification and technology. *Advances Clin Chem* **27**: 303-353, 1989
- (118) Vieira, J. & Messing, J. Production of single-stranded plasmid DNA. *Methods Enzymol* **153**: 3-11, 1987
- (119) Watanabe, M., Wallace, P. K., Keler, T., Deo, Y. M., Akewanlop, C., Hayes, D. F.: Antibody dependent cellular phagocytosis (ADCP) and antibody dependent cellular cytotoxicity (ADCC) of breast cancer cells mediated by bispecific antibody, MDX-210. *Breast Cancer Res Treat* **53**: 199-207, 1999
- (120) Watters, J. M., Telleman, P., Junghans, R. P.: An optimized method for cell-based phage display panning. *Immunotechnology* **3**: 21-29, 1997
- (121) Welt, S., Divgi, C. R., Kemeny, N., Finn, R. D., Scott, A. D., Graham, M., St Germain, J., Richards, E. C., Larson, S. M., Oettgen, H., F. and et al.: Phase I/II study of <sup>131</sup>Iodine-labeled monoclonal antibody A33 in patients with advanced colon cancer. *J Clin Oncol* **12**: 1561-1571, 1994
- (122) Welter, C., Reichert, G., Zang, K. D.: Increased amount of a mitochondria-associated 21 x 10<sup>3</sup> dalton protein in human gastrointestinal tumors. *J Cancer Res Clin Oncol* **114**: 411-414, 1988
- (123) Winnacker, E.-L.: *Gene und Klone. Eine Einführung in die Gentechnologie*. VCH Verlagsgesellschaft GmbH, 1984
- (124) Yamagata, K., Sanders, L. K., Kaufmann, W. E., Yee, W., Barnes, C. A., Nathans, D., Worley, P. F.: rheb, a growth factor- and synaptic activity-regulated gene, encodes a novel ras-related protein. *J Biol Chem* **269**: 16333-16339, 1994
- (125) Yee, W. M. & Worley, P. F.: Rheb interacts with Raf-1 Kinase and may function to integrate growth factor- and protein kinase A-dependant signals. *Mol Cell Biol* **17**: 921-933, 1997

## Eigene Publikationen

Barth, S. & Weidenmüller, U., Tur, M. K., Schmidt, M. F. G., Engert, A.: Combining phage display and screening of cDNA expression libraries: A new approach for identifying the target antigen of a scFv preselected by phage display. *J Mol Biol (in Druck)* 2000